Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/57717
Title: Quetiapine monotherapy versus placebo in the treatment of children and adolescents with bipolar depression: A systematic review and meta-analysis
Authors: Benchalak Maneeton
Suwannee Putthisri
Narong Maneeton
Pakapan Woottiluk
Sirijit Suttajit
Chawanun Charnsil
Manit Srisurapanont
Keywords: Medicine
Neuroscience
Issue Date: 4-Apr-2017
Abstract: © 2017 Maneeton et al. Background: Some studies have indicated the efficacy of quetiapine in the treatment of bipolar depression in adult patients. However, its efficacy has been not shown in child and adolescent patients. Objective: This systematic review purposefully determined the efficacy and acceptability of quetiapine in the treatment of children and adolescents with bipolar depression. Data sources: A database search of EMBASE, PubMed, CINAHL, and Cochrane Controlled Trials Register was carried out in March 2016. All randomized controlled trials (RCTs) of bipolar depression in children and adolescents were considered for inclusion in this review. Study eligibility criteria, participants, and interventions: RCTs of quetiapine in the treatment of child and adolescent patients with bipolar depression with end point outcomes were included in this study. Languages were not limited. Study appraisal and synthesis methods: The full-text versions of relevant clinical studies were thoroughly examined and extracted. The primary efficacy of outcome was measured by using the pooled mean-changed scores of the rating scales for bipolar depression. However, the response and remission rates were also measured. Results: A total of 251 randomized patients in the three RCTs of quetiapine versus placebo in the treatment of bipolar depression for children and adolescents were eligible in this review. The pooled mean-changed score of the quetiapine-treated group was not greater than that of the placebo-treated group. Similarly, the pooled response and remission rates were not different between the two groups. The pooled overall discontinuation rate and the discontinuation rate due to adverse events were not different between the two groups. Limitations: Limited studies were eligible in this review. Conclusion: According to the findings in this review, quetiapine may not be efficacious in the treatment of bipolar depression in children and adolescents. Its acceptability, however, was comparable to a placebo. Therefore, the use of quetiapine in children and adolescents with bipolar depression is not recommended. Further well-defined clinical studies should be performed to confirm these outcomes.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85018525090&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/57717
ISSN: 11782021
11766328
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.